OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a type of malignant tumor with a five-year survival rate of less than 10%. Gemcitabine (GEM) is the most commonly used drug for PDAC chemotherapy. However, a vast majority of patients with PDAC develop resistance after GEM treatment. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Jinsheng, Li, Hui, Liu, Yang, Xie, Yongjie, Yu, Jie, Sun, Huizhi, Xiao, Di, Zhou, Yizhang, Bao, Li, Wang, Hongwei, Gao, Chuntao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602561/
https://www.ncbi.nlm.nih.gov/pubmed/34804914
http://dx.doi.org/10.3389/fonc.2021.698302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602561/
https://www.ncbi.nlm.nih.gov/pubmed/34804914
http://dx.doi.org/10.3389/fonc.2021.698302

Ejemplares similares